Novartis CAR-T therapy second-line treatment of B-NHL clinical study failed!

Image source: Yaozhi Data

Overview of Global CAR-T Therapy Approval

Data source: Yaozhi data

The country is gradually entering the harvest period

CAR-T therapy is considered to be one of the most promising cancer treatments, and its launch has opened a new milestone in the history of human anti-cancer
.
At the same time, it has also triggered an upsurge in cell therapy research and development.
According to a previous report by Nature Reviews Drug Discovery, CAR-T occupies a leading position in the global cell therapy drug research and development pipeline.

According to statistics, as of the end of June, a total of 670 CAR-T clinical trials are ongoing worldwide, and China and the United States account for approximately 91.
3% of the world
.

Among them, the number of CAR-T clinical trials in China has shown a "blowout" since 2016.
The number of domestic CAR-T clinical trials registered on Clinicaltrials has exceeded 365, ranking first in the world, accounting for 53.
3%
.

At the same time, CAR-T is considered to be one of the most promising areas for domestic companies to keep up with the global R&D pace.
At present, Fosun Kate’s Achilles injection has been approved for marketing.
Combined antigen receptor (CAR) T cell therapy relma-cel injection as a new drug for the third-line therapy of relapsed or refractory B-cell lymphoma has been approved for marketing, or it will become the second domestic CAR- T therapy
.

Overview of domestic enterprise CAR-T layout and research progress

Data source: Yaozhi data, corporate announcements and other public data

Note: The above data is manually searched and sorted out.
If there is any omission, please leave a message to add and discuss!

Reference: Novartis' Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeeded

Editor in charge: Sanqi